AHA GUIDELINES Bundle (free trial)

High Blood Pressure

AHA GUIDELINES Apps brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1512419

Contents of this Issue

Navigation

Page 14 of 87

15 3.2.2. White-Coat Hypertension and Masked Hypertension, and White-Coat Effect and Masked Uncontrolled Hypertension COR LOE Recommendations 2a B-NR 1. In adults with untreated office SBP ≥130 mm Hg or DBP ≥80 mm Hg, and without office SBP ≥160 mm Hg or DBP ≥100 mm Hg, it is reasonable to exclude white-coat hypertension using out-of-office BP monitoring before a diagnosis of hypertension is made. 2a B-NR 2. In adults with white-coat hypertension or masked hypertension, out-of-office BP monitoring is reasonable to exclude transition to a diagnosis of sustained hypertension. 2a C-LD 3. In adults with apparent treatment-resistant hypertension on office BP, it is reasonable to exclude white-coat effect, a form of pseudoresistance, using out-of-office BP monitoring. 2a B-NR 4. In adults who are taking antihypertensive medication and have elevated office BP (office SBP ≥130 mm Hg or DBP ≥80 mm Hg ) but do not have resistant hypertension or office SBP ≥160 mm Hg or DBP ≥100 mm Hg, it is reasonable to exclude white-coat effect using out-of-office BP monitoring. 2b B-NR 5. In adults with untreated office SBP <130 mm Hg and DBP <80 mm Hg, it may be reasonable to exclude masked hypertension using out-of-office BP monitoring. 2b B-NR 6. In adults who are taking antihypertensive medication and have office SBP <130 mm Hg and DBP <80 mm Hg, it may be reasonable to exclude masked uncontrolled hypertension using out-of-office BP monitoring.

Articles in this issue

Archives of this issue

view archives of AHA GUIDELINES Bundle (free trial) - High Blood Pressure